BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AZD3632 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of AZD3632\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07155226-2990@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20290215
DTEND;VALUE=DATE:20290216
SUMMARY:AZD3632: Phase 1/2 readout est. (NCT07155226)
DESCRIPTION:AZD3632\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Study of 
 AZD3632 Monotherapy or in Combination With Anticancer Agents in Participan
 ts With Advanced Haematologic Malignancies With KMT2Ar\, NPM1m\, or Other 
 Genotypes Associated With HOX Overexpression\nEstimated primary completion
 : 15 February 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/a
 zd3632#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07155226
URL:https://assetmemo.bio/drug/azd3632#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
